A CRISPR/Cas9 based strategy to attenuate the beta-amyloid pathway

Here we introduce a strategy to edit endogenous amyloid precursor protein (APP) at the extreme C-terminus and selectively attenuate the amyloidogenic pathway – a key pathologic cascade in Alzheimer’s disease (AD).